Beta

Polaryx therapeutics, inc. common stockPLYX.US Overview

US StockHealthcare
(No presentation for PLYX)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

PLYX AI Insights

PLYX Overall Performance

PLYX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PLYX Recent Performance

11.05%

Polaryx therapeutics, inc. common stock

-1.10%

Avg of Sector

-0.49%

S&P500

PLYX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check PLYX's Trend

PLYX Key Information

PLYX Valuation Metrics

PLYX Profile

Price of PLYX

PLYX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PLYX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.06
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
50.30
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.06
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
50.30
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is PLYX's latest earnings report released?

    The most recent financial report for Polaryx therapeutics, inc. common stock (PLYX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PLYX's short-term business performance and financial health. For the latest updates on PLYX's earnings releases, visit this page regularly.

  • How much cash does PLYX have?

    At the end of the period, Polaryx therapeutics, inc. common stock (PLYX) held Total Cash and Cash Equivalents of 5.14M, accounting for 0.99 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What are the PEG ratio and PE ratio of PLYX?

    The latest valuation data shows Polaryx therapeutics, inc. common stock (PLYX) has a Price-To-Earnings (PE) ratio of -33.93 and a Price/Earnings-To-Growth (PEG) ratio of -0.88. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.